Compulsory use of the 7-valent pneumococcal conjugate vaccine in the framework of national pediatric immunization schedules of the developed countries resulted in significant decrease in the prevalence of the pneumococcal infections induced by the vaccinal serotypes. However, a growth in prevalence of the pneumonia and acute otitis media caused by non-vaccinal strains has also been observed. This required introduction of a new 13-valent pneumococcal conjugate vaccine with a wider range of pneumococcal population coverage. The experience of application accumulated in various countries (2010 onwards) and results of the authors' observations indicate high safety of the 13-valent pneumococcal conjugate vaccine for both healthy under-5 children and patients with various medical issues. The article presents results of the 13-valent pneumococcal conjugate vaccination tolerance assessment. The study involved 110 children from 2 months to 5 years of age. In most cases immunization concurred with other pediatric vaccines. The incidence of local reactions in vaccinated children did not exceed 33%, of generalized reactions-11%. The authors observed a comparable incidence of side reactions in both virtually healthy children and children with various medical issues.

No abstract

BackgroundPertussis is a highly contagious bacterial infection with a respiratory route of transmission. It remains an important public health problem in Russia and in the world. The only confirmed way of specific prevention of pertussis is vaccination. There is only one booster dose against pertussis at the age of 18 months with DTwP in Russia. This vaccine is not administered in children after 4 years of age due to its reactogenicity. The alternative way to the whole cell pertussis vaccination is the administration of DTaP, which can be used in older children.Aimsto study tolerability of vaccines containing acellular pertussis after 4 years of age.MethodsThe retrospective study included the analysis of safety of DTaP vaccines in 123 children aged 4–9 years from 01.12.2014 to 31.12.2015. It included 62 healthy children, 30 with allergic diseases and 31 with other chronic diseases.ResultsIn the post-vaccination period (3 days after the vaccination) local reactions were observed in 39 (32%) subjects, where 19 (31%) were healthy children, 11 (37%) – with allergic disease, 9 (29%) – with other pathology. Moreover, severe local reactions in the injection site occurred in 15% of subjects. Half of these children had different allergic diseases. Common reactions were observed in 25 (20%) children, where 11 (18%) were healthy, 6 (20%) – with allergic pathology and 8 (26%) children with other chronic diseases. Only 7% of the common reactions were considered severe. During the first week after the vaccination, no exacerbations of allergy or any other chronic diseases were observed.ConclusionA good tolerability of DTaP was demonstrated in children after 4 years of age in both healthy subjects and those having different chronic diseases. Apart from the children with allergic pathology who had severe local reactions more frequently, these two groups had no difference in the prevalence and severity of post-vaccination adverse reactions.

Despite the fact that according to the guidelines of the World Health Organization all patients with allergic disorders should be annually vaccinated against influenza, regardless of the form or severity of the disease and ongoing drug therapy, that is still not applicable in practice. This fact entails at least two negative outcomes: the risk of infectious disease and its complications, as well as increased likelihood of exacerbation of the allergic disease against a background of the intercurrent infection. The aim of the study was to investigate the effectiveness and tolerability of domestic and foreign vaccines against the flu in children with allergic diseases. The study demonstrated good tolerability of the researched vaccines, absence of evident local and/or systemic reactions and of exacerbations of allergic diseases. The study found that vaccination completely protects children from the flu and significantly reduces the incidence of ARI, leading to an increase in the remission period and lower incidence of exacerbations of the underlying disease.